Prospective evaluation of tumor markers (c-erbB-2 oncoprotein, CEA and CA 15.3) in patients with locoregional breast cancer.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Anticancer Research

• Publication date

  2003-03-01

• Fields of study

  Medicine

• Identifiers
  PMID 12820345
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• The Prognostic Value of the Tumor Marker CA 15–3 at Initial Diagnosis of Patients with Breast Cancer

  2000cited by this paper
• CA 15–3: A Prognostic Marker in Breast Cancer

  2000cited by this paper
• Tumour markers CEA and CA 15-3 as Prognostic factors in breast cancer--univariate and multivariate analysis.

  1999cited by this paper
• c-erbB-2 oncoprotein, CEA, and CA 15.3 in patients with breast cancer: prognostic value

  1998cited by this paper
• Influence of circulating c-erbB-2 serum protein on response to adjuvant chemotherapy in node-positive breast cancer patients

  1997cited by this paper
• Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers.

  1996cited by this paper
• C-erbB-2 oncoprotein in the sera and tissue of patients with breast cancer. Utility in prognosis.

  1996cited by this paper
• Humoral immune response to polymorphic epithelial mucin (MUC-1) in patients with benign and malignant breast tumours.

  1996cited by this paper
• Serial serum c‐erbB‐2 levels in patients with breast carcinoma

  1996cited by this paper
• Significance of cytokeratin markers TPA, TPA (cyk), TPS and CYFRA 21.1 in metastatic disease.

  1996cited by this paper
• An evaluation of preoperative CA 15-3 measurement in primary breast carcinoma.

  1995cited by this paper
• The usefulness of CA15.3, mucin-like carcinoma-associated antigen and carcinoembryonic antigen in determining the clinical course in patients with metastatic breast cancer

  1995cited by this paper
• CA15-3, CASA, MSA, and TPS as diagnostic serum markers in breast cancer

  1995cited by this paper
• Suppression of cellular aggregation by high levels of episialin.

  1992cited by this paper
• The tumour associated antigen CA15.3 in primary breast cancer. Evaluation of 667 cases.

  1991cited by this paper
• Pre-operative tumour marker levels in patients with breast cancer and their prognosis.

  1990cited by this paper
• The Role of Serum CEA as a Prognostic Indicator in Stage II and III Breast Cancer Patients Treated With Adjuvant Chemotherapy

  1989cited by this paper
• Pretreatment concentrations of breast carcinoma antigen (CA 15.3) and mucin-like carcinoma-associated antigen in patients with carcinoma of the breast.

  1989cited by this paper
• Immunoperoxidase localization of lactalbumin in malignant breast neoplasms.

  1982cited by this paper

• Downregulation of hsa_circ_0006220 and its correlation with clinicopathological factors in human breast cancer.

  2021cites this paper
• GASTROİNTESTİNAL VE MEME MALİGN NEOPLASMLI PREOPERATİF HASTALARDA, CEA, CA 19-

  2020cites this paper
• Plasma TuM2-PK correlates with tumor size, CRP and CA 15-3 in metastatic breast carcinomas; short versus long term follow up study of the Egyptian breast cancer patients

  2017cites this paper
• The Significance of Serum HER2 Levels at Diagnosis on Intrinsic Subtype-Specific Outcome of Operable Breast Cancer Patients

  2016cites this paper
• Serum Human Epidermal Growth Factor 2 Extracellular Domain as a Predictive Biomarker for Lapatinib Treatment Efficacy in Patients With Advanced Breast Cancer.

  2016cites this paper
• Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.

  2015cites this paper
• Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer.

  2014cites this paper
• Role of serum carcinoembryonic antigen (CEA) as a tumor marker in breast cancer

  2014cites this paper
• Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.

  2014cites this paper
• Evaluation of Serum Levels of HER2, MMP-9, Nitric Oxide, and Total Antioxidant Capacity in Egyptian Breast Cancer Patients: Correlation with Clinico-Pathological Parameters

  2013cites this paper
• Serum tumour markers as a diagnostic and prognostic tool in Libyan breast cancer

  2012cites this paper
• Circulating levels of HER-2/neu oncoprotein in breast cancer

  2012cites this paper
• Elevated HER2 extracellular domain level in primary breast cancer with HER2 overexpression predicts early failure of adjuvant trastuzumab.

  2012cites this paper
• Relationship between serum HER2 extracellular domain levels, tissue HER2 expression, and clinico-pathological parameters in early stage breast cancer.

  2012cites this paper
• High serum HER2 extracellular domain levels: correlation with a worse disease-free survival and overall survival in primary operable breast cancer patients

  2012influential citation
• Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.

  2011cites this paper
• Doit-on doser le marqueur circulant ECD/HER-2 chez les patientes atteintes d’un cancer mammaire ?

  2011cites this paper
• Clinical Usefulness of Cancer Markers in Primary Breast Cancer

  2011cites this paper
• Oral contraceptive use and salivary C-erbB-2, CEA and CA15-3 in healthy women: a case-control study.

  2011cites this paper
• Correlation between c-erbB2 expression, lymphovascular invasion and other biological and clinical prognostic factors and preoperative tumor markers in patients with early-stage and locally advanced breast cancer.

  2011cites this paper
• [Clinical usefulness of circulating ECD/HER-2 measurement for breast cancer patients' management].

  2011cites this paper
• Evaluation of tumor markers (HER-2/neu oncoprotein, CEA, and CA 15.3) in patients with locoregional breast cancer: prognostic value

  2010cites this paper
• Prospective evaluation of carcinoembryonic antigen (CEA) and carbohydrate antigen 15.3 (CA 15.3) in patients with primary locoregional breast cancer.

  2010cites this paper
• Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

  2010cites this paper
• 12 Monitoring serum HER2 levels in the neoadjuvant “Geparquattro” trial – a decrease predicts pathological complete remission

  2010cites this paper
• Monitoring serum HER2 levels during neoadjuvant trastuzumab treatment within the GeparQuattro trial

  2010cites this paper
• Prospective Evaluation of Carcinoembryonic Antigen (CEA) and Cancer Antigen 15.3 (CA 15.3) in Patients with Primary Locoregional Breast Cancer

  2010cites this paper
• Perioperative serum VEGF and extracellular domains of EGFR and HER2 in early breast cancer.

  2009cites this paper
• Prognostic Significance of Serum HER 2 and CA 15-3 at the Time of Diagnosis of Metastatic Breast Cancer

  2009cites this paper
• Das HER-2/neu-Shed Antigen beim Mammakarzinom zum Zeitpunkt der Primärdiagnose

  2009cites this paper
• Relationship Between Tumor Markers CEA and CA 15-3 , TNM Staging , Estrogen Receptor Rate and MIB-1 Index in Patients with pT 1-2 Breast Cancer *

  2009cites this paper
• Changes of Serum HER 2 Status during Clinical Course of Metastatic Breast Cancer Patients

  2009cites this paper
• Value and limitations of measuring HER-2 extracellular domain in the serum of breast cancer patients.

  2009cites this paper
• Alternative antibody for the detection of CA125 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® OV Monitor assay on the UniCel® DxI 800 Immunoassay System

  2008cites this paper
• Evaluation of serum HER2 extracellular domain in early breast cancer patients: correlation with clinicopathological parameters and survival.

  2008cites this paper
• Long-term prognostic study of carcinoembryonic antigen (CEA) and carbohydrate antigen 15-3 (CA 15-3) in breast cancer

  2008influential citation
• Tumor markers in breast cancer – european group on tumor markers (EGTM) recommendations

  2008cites this paper
• The influence of serum HER-2 levels and HER-2 codon 655 polymorphism on breast cancer outcome.

  2008cites this paper
• Alternative antibody for the detection of CA15-3 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access® BR Monitor assay on the UniCel® DxI 800 Immunoassay System

  2008cites this paper
• Prognostic factors in Hungarian breast cancer patients.

  2007cites this paper
• Serum c‐erbB‐2 protein is a useful marker for monitoring tumor recurrence of the breast

  2007cites this paper
• Concentraciones séricas preoperatorias de antígeno carbohidrato 15.3 y antígeno carcinoembrionario y características clínico-biológicas tisulares de los carcinomas mamarios

  2006cites this paper
• [Preoperative serum CA15.3 and CEA levels and clinical-biological parameters in breast tumors].

  2006cites this paper
• CA15-3 and alkaline phosphatase as predictors for breast cancer recurrence: a combined analysis of seven International Breast Cancer Study Group trials.

  2006cites this paper
• Do Serum Angiogenic Growth Factors Provide Additional Information to That of Conventional Markers in Monitoring the Course of Metastatic Breast Cancer?

  2006cites this paper
• Effectiveness of Follow-Up for Breast Cancer Patients

  2006cites this paper
• Vector Targeting in Gene Therapy

  2006cites this paper
• A multi-center quality control study of different CA15-3 immunoassays.

  2005cites this paper
• Tumor Markers in Breast Cancer – European Group on Tumor Markers Recommendations

  2005cites this paper
• Tissue expression and serum levels of the oncoprotein HER-2/neu in 157 primary breast tumours.

  2005cites this paper
• SERUM LEVEL OF HER-2 EXTRACELLULAR DOMAIN IN IRANIAN PATIENTS WITH BREAST CANCER: A FOLLOW-UP STUDY

  2005cites this paper
• A CASE OF HEPATIC METASTASIS OF BREAST CANCER FOUND WITH ELEVATION OF SERUM HER-2/neu PROTEIN

  2005cites this paper
• Clinical relevance of tumor markers for the control of chemotherapy.

  2005cites this paper
• Prognostic utility of a glycoprotein tumor-associated antigen (TA90) specific immune complex assay in patients with cancer

  2004cites this paper
• Prognostic significance of serum HER2 and CA 15-3 at the time of diagnosis of metastatic breast cancer.

  2004cites this paper
• Serum tumor markers in patients with breast cancer

  2004cites this paper
• Improved Targeting of Photosensitizers by Intratumoral Administration of Immunoconjugates

  2004cites this paper
• Improved Targeting of Photosensitizers by Intratumoral Administration of Immunoconjugates

  2004cites this paper
• Changes in serum IgG oligosaccharide chains with prostate cancer progression.

  2004cites this paper
• Changes of serum HER2 status during clinical course of metastatic breast cancer patients.

  2004cites this paper
• Relationship between tumor markers CEA and CA 15-3, TNM staging, estrogen receptor rate and MIB-1 index in patients with pT1-2 breast cancer.

  2003cites this paper